Latest Biotech News

Tempus AI agreed to buy Personalis for $1.5 billion, stepping deeper into minimal residual disease (MRD) testing and expanding its tumor-informed liquid biopsy portfolio. Under the deal terms,...

Bristol Myers Squibb and Nvidia said they will expand pharma’s AI compute footprint, targeting “the most powerful AI factory in life sciences.” BMS plans to build new infrastructure around an...

Researchers reported the world’s first gene-edited biting midges (Culicoides), opening a new path for studying how these vectors transmit livestock diseases. The advance targets Culicoides, small...

A new whole-genome study identified early genomic indicators that Schistosoma mansoni may be developing reduced sensitivity to praziquantel, the sole widely used drug for schistosomiasis control....

Researchers published a pan-cancer patient-derived organoid (PDO) platform designed for precision oncology modeling and therapeutic vulnerability screening. In Science Advances, the team described...

Sanford Burnham Prebys researchers reported that upregulating SORLA suppresses multiple pathological features in an aged mouse model of tauopathy. In Science Advances, the team tied the...

Latigo Biotherapeutics disclosed IPO plans to fund development of its oral Nav1.8 inhibitor LTG-001, positioning the program for late-stage expansion in acute and broader post-surgical and...

A new analysis argued that implementation science training should become a core capability for clinical trial workforces to improve how evidence translates into routine healthcare. The study...

University of Virginia researchers identified a widespread source of error in a popular genomics method and created a free machine-learning tool to correct it. The work, described as improving...

A new perspective focused on scalable cell therapy manufacturing argues that developers should shift from research workflows to GMP-ready systems earlier in development. The article emphasizes...

Tempus AI agreed to acquire cancer test-maker Personalis for about $1.5 billion, marking a decisive consolidation push in minimal residual disease (MRD) testing. The deal pairs Personalis’s...

Researchers published a pan-cancer patient-derived organoid (PDO) platform in Science Advances that claims high fidelity to the original tumors and yields actionable therapeutic vulnerabilities....

Scientists at Sanford Burnham Prebys reported in Science Advances that SORLA upregulation suppressed multiple pathological features in an aged tauopathy mouse model. The study centers on tau...

A plasma proteomics study identified protein patterns linked to Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal dementia, reporting a 21-protein panel for distinguishing...

Legend Biotech’s shares fell about 10% despite reporting record Carvykti sales, after remarks on a Johnson & Johnson earnings call drew investor concern. J&J’s Worldwide Chair of Innovative...

Researchers and clinicians debated delivery constraints for in vivo CAR T therapeutics at BIO Asia–Taiwan 2026, positioning in vivo CAR T as a potential “second revolution” in cell and gene...

A study from Albert Einstein College of Medicine, published in PLOS Biology, links late-adolescent brain remodeling in mice to temporary instability in contextual memory circuits. The work centers...

Preclinical and translational discussions in oncology aside, a dedicated investigation addressed how blood plasma protein signatures can correspond to distinct neurodegenerative dementia...

Bristol Myers Squibb and Nvidia said they will expand AI infrastructure to build what BMS calls the “most powerful” AI factory in life sciences. The company plans to deploy Nvidia DGX SuperPOD...

Merck KGaA’s Lipfendra became the first oral PCSK9 inhibitor approved by the FDA for lowering LDL cholesterol in adults with high cholesterol. The approval advances a new delivery approach for...